Brito M.J.a,b· Quintas A.c· Passos F.c· Alves A.T.a· Félix A.d,e· Martins C.G.e,f,g

Author affiliations

aDepartment of Pathology, Hospital Garcia de Orta, Almada, Portugal
bDepartment of Pathology, Champalimaud Foundation, Lisboa, Portugal
cDepartment of Gynecology and Obstetrics, Hospital Garcia de Orta, Almada, Portugal
dDepartment of Pathology, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal
eNOVA Medical School, Nova University of Lisbon, Campo dos Mártires da Pátria, Lisbon, Portugal
fComprehensive Health Research Centre (CHRC), NOVA Medical School, Nova University of Lisbon, Lisbon, Portugal
gChronic Diseases Research Centre (CEDOC), NOVA Medical School, Nova University of Lisbon, Lisbon, Portugal

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: April 29, 2022
Accepted: August 26, 2022
Published online: October 27, 2022

Number of Print Pages: 11
Number of Figures: 2
Number of Tables: 5

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Abstract

Introduction: To better understand the role of mucosa immunity in the development of cervical carcinoma in HIV infection, cervical lymphocyte subsets were characterized in HIV+ and HIV− women, as well as their relation to HPV-associated cervical lesions. Methods: Eighty-three (52 HIV+, 31 HIV−) cell suspensions of cervicovaginal lavage (CVL) and 52 HIV+ peripheral blood (PB) samples were assessed by flow cytometry to evaluate lymphoid populations. High-risk (HR) HPV was assessed in liquid-based cytology and HIV mRNA in PB in the same patients. Results: Cervical CD4+ T cells and CD4+/CD8+ ratio were decreased (p < 0.0001) and cervical CD8+ T cells were increased (p = 0.0080) in HIV+ women. These patients had lower CD4+ T-cell percentages in CVL compared to PB (p = 0.0257), and the opposite was true for CD8+ T cells (p = 0.0104). They also had a higher prevalence of high-grade squamous intraepithelial lesions (SILs) with an increased prevalence of HR HPV. Cervical CD8+ T cells were increased in HR HPV+ patients (p = 0.0300) and related to higher prevalence of SILs (p = 0.0001). Discussion/Conclusion: Cervical lymphoid populations can be characterized by flow cytometry, showing a distinct cervical T-cell compartment in HIV+ women. This may represent a surrogate risk marker of HPV-associated cervical lesions in this population and prompt further research on this subject, contributing to improving patients’ management.

© 2022 S. Karger AG, Basel

References Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013 Sep;382(9895):889–99. Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018 Mar;32(6):795–808. Adler DH, Kakinami L, Modisenyane T, Tshabangu N, Mohapi L, De Bruyn G, et al. Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. AIDS. 2012 Aug;26(13):1645–52. Blitz S, Baxter J, Raboud J, Walmsley S, Rachlis A, Smaill F, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis. 2013 Aug;208(3):454–62. Boasso A, Shearer GM, Chougnet C. Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it? J Intern Med. 2009 Jan;265(1):78–96. Borges ÁH, Dubrow R, Silverberg MJ. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS. 2014 Jan;9(1):34–40. Engels EA. 150 HIV and cancer: current trends and insights. JAIDS J Acquir Immune Defic Syndr. 2009 Jun;51(Suppl 2). Massad LS, Seaberg EC, Watts DH, Minkoff H, Levine AM, Henry D, et al. Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer. 2009 Feb;115(3):524–30. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Heal. 2021 Feb;9(2):e161–9. Bere A, Denny L, Naicker P, Burgers WA, Passmore JAS. HIV-specific T-cell responses detected in the genital tract of chronically HIV-infected women are largely monofunctional. Immunology. 2013 Jul;139(3):342–51. Brito MJ, Quintas A, Sequeira P, Alves AT, Martins C, Félix A. Detection of HIV mRNA in routine liquid based cytology specimens of HIV infected women. Cytopathology. 2021 Sep;32(5):640–5. Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath MJ. HIV-1 induces cytotoxic t lymphocytes in the cervix of infected women. J Exp Med. 1997 Jan;185(2):293–303. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, et al. HIV-1-specific mucosal CD8 + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol. 2000 Feb;164(3):1602–11. Gumbi PP, Nkwanyana NN, Bere A, Burgers WA, Gray CM, Williamson A-L, et al. Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection. J Virol. 2008 Sep;82(17):8529–36. Nayar R, Wilbur DC, editors. The bethesda system for reporting cervical cytology. Cham: Springer International Publishing; 2015. Harari A, Chen Z, Burk RD. Human papillomavirus genomics: past, present and future. 2014. p. 1–18. Juno JA, Boily-Larouche G, Lajoie J, Fowke KR. Collection, isolation, and flow cytometric analysis of human endocervical samples. J Vis Exp. 2014 Jul;89. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med. 1997 Oct;337(18):1267–74. Brito MJ, Sequeira P, Silva I, Quintas A, Martins C, Félix A. CD4+ and CD8+ cell populations in HIV-positive women with cervical squamous intra-epithelial lesions and squamous cell carcinoma. Int J Infect Dis. 2021 Feb;103:370–7. Nava-Memije K, Hernández-Cortez C, Ruiz-González V, Saldaña-Juárez CA, Medina-Islas Y, Dueñas-Domínguez RA, et al. Bacterial vaginosis and sexually transmitted infections in an HIV-positive cohort. Front Reprod Heal. 2021 Apr;3. Tao L, Wang S, Kang G, Jiang S, Yin W, Zong L, et al. PD-1 blockade improves the anti-tumor potency of exhausted CD3 + CD56 + NKT-like cells in patients with primary hepatocellular carcinoma. Oncoimmunology. 2021 Jan;10(1):2002068. Fonseca S, Pereira V, Lau C, Teixeira MDA, Lima M, Bini-Antunes M, et al. Human peripheral blood gamma delta T Cells: report on a series of healthy Caucasian Portuguese adults and comprehensive review of the literature. Cells. 2020 Mar;9(3):729. Juno JA, Eriksson EM. γδ T-cell responses during HIV infection and antiretroviral therapy. Clin Transl Immunology. 2019 Jan;8(7). Rischin D, Gil-Martin M, González-Martin A, Braña I, Hou JY, Cho D, et al. PD-1 blockade in recurrent or metastatic cervical cancer: data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020 Nov;159(2):322–8. Article / Publication Details

First-Page Preview

Received: April 29, 2022
Accepted: August 26, 2022
Published online: October 27, 2022

Number of Print Pages: 11
Number of Figures: 2
Number of Tables: 5

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.